Lee PC, Klaeger S, Le PM, et al. Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J Clin Invest. 2022;132(13). doi:10.1172/JCI151666
Oliveira G, Stromhaug K, Cieri N, et al. Landscape of helper and regulatory antitumour CD4 T cells in melanoma. Nature. 2022;605(7910):532-538. doi:10.1038/s41586-022-04682-5
Hodis E, Triglia ET, Kwon JYH, et al. Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment. Science. 2022;376(6592):eabi8175. doi:10.1126/science.abi8175
Pan D, Kobayashi A, Jiang P, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359(6377):770-775. doi:10.1126/science.aao1710
Artomov M, Stratigos AJ, Kim I, et al. Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing. J Natl Cancer Inst. 2017;109(12). doi:10.1093/jnci/djx083
Zhou XA, Louissaint A, Wenzel A, et al. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. J Invest Dermatol. 2018;138(11):2365-2376. doi:10.1016/j.jid.2018.04.038
Nirschl CJ, Suárez-Fariñas M, Izar B, et al. IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. Cell. 2017;170(1):127-141.e15. doi:10.1016/j.cell.2017.06.016
Shukla SA, Bachireddy P, Schilling B, et al. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018;173(3):624-633.e8. doi:10.1016/j.cell.2018.03.026
Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888-898. doi:10.1182/blood-2017-08-802470
Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96. doi:10.1200/JCO.2010.33.2312